HOW WE WORK WITH BIOPHARMA COMPANIES
CHA conducts surveys (industry-wide and targeting specific segments of the industry) and trend analysis to assist biopharmaceutical companies in strategic planning and investment justification. Surveys can cover a broad range of scientific areas through a database of more than 500,000 leading scientists and managers across industry and academia.
Surveys may be implemented in conjunction with expert interviews or other channels to optimize the project plan on behalf of the biopharma company, eg. to leverage outsourcing opportunities in China, or to explore the industry's use of a new process or technology.
CHA creates and manages peer-to-peer networks and online communities to enable industry professionals to collaborate, share ideas and learn through participation in live webinars and online discussion forums. Communities are professionally moderated, and feature the industry's most prominent thought leaders and subject matter experts. Communities feature archived content as a reference library for members. Membership in our communities is free for biopharmaceutical company executives.
CHA's Technology Evaluation Consortia (TEC) harness the combined expertise of representatives from top pharmaceutical companies to identify new predictive safety technologies and qualify the platforms using a shared library of compounds.
Member Benefits for Pharma Companies
• Reduction in time, costs and risks associated with evaluations of new technology platforms
• Existing library and infrastructure to efficiently engage in assessing novel technologies
• One-time cost for resource-intensive tasks such as compound and data collection
• Collaborative scale improves experiment validity
• Peer-to-peer learning for optimal knowledge accumulation
HOW WE WORK WITH TECHNOLOGY PROVIDERS
We leverage our vast industry database to provide technology innovators with a channel to reach multiple pharmaceutical companies simultaneously and gain valuable feedback on their products or services.
Our array of networks within the biopharma market (including a database of more than 500k names) allows us to forge relationships between innovators and biopharma decision makers. We use our community and social media programming to communicate a technology provider's value proposition and position in the marketplace.
With our product evalution consortium of biopharma companies, we offer technology providers a one-stop channel to access multiple biopharma companies for input into their technology's design and overall marketing plan. This provides a uniqe 4-6 month relationship-building opportunity with potential customers.